Your browser doesn't support javascript.
loading
A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne, Kenneth R; Butler, Jeannene; Borowski, Virna B; Fuentes-Pesquera, Angel R; Blevitt, Jonathan M; Huang, Shenlin; Li, Ronghua; Connolly, Peter J; Greenberger, Lee M.
Affiliation
  • LaMontagne KR; Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA. Kenneth.lamontagne@novartis.com
Angiogenesis ; 12(3): 287-96, 2009.
Article in En | MEDLINE | ID: mdl-19544081
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vascular Endothelial Growth Factor Receptor-2 / Protein Kinase Inhibitors / Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Angiogenesis Journal subject: HEMATOLOGIA Year: 2009 Document type: Article Affiliation country: Estados Unidos Country of publication: Alemania
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vascular Endothelial Growth Factor Receptor-2 / Protein Kinase Inhibitors / Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Angiogenesis Journal subject: HEMATOLOGIA Year: 2009 Document type: Article Affiliation country: Estados Unidos Country of publication: Alemania